Os 179 melhores médicos de biópsia mamária do mundo

O Dr. Baha Zengel é cirurgião geral no Medicalpoint International Hospital. Especializa-se em cirurgia oncoplástica da mama e doenças da tiroide. Possui doutoramento em Oncologia Básica pela Universidade Dokuz Eylül. O Dr. Zengel é membro fundador do conselho da Associação de Oncologia Básica. Trabalha numa unidade acreditada pela JCI em Esmirna.

• Realiza mastectomias conservadoras da mama e reconstruções simultâneas.
• Especialista em técnicas de localização ROLL e SNOLL para lesões não palpáveis.
• Trata pacientes com doenças da vesícula biliar através de colecistectomia laparoscópica.
• Ex-membro do conselho da Associação de Cirurgia da Região do Egeu.

O Dr. Tahsin Ozatli é professor associado de oncologia no Istinye University Liv Hospital. Ele é especializado no diagnóstico e tratamento do câncer de mama e tumores gastrointestinais.

• Promovido a professor associado em reconhecimento à sua experiência clínica e acadêmica
• Treinado na Clínica de Oncologia de Ancara, um importante centro de diagnóstico de câncer
• Ex-especialista em medicina interna no Hospital Estadual de Malatya
• Coordena procedimentos de biópsia de mama para identificação precisa das características do tumor
• Experiente em cuidados oncológicos no Hospital Regional de Treinamento e Pesquisa de Erzurum

O Dr. Cemil Bilir é professor de oncologia médica no hospital VM Medical Park Pendik, em Istambul. Especializa-se em imunoterapia e quimioterapia para cancros do pulmão, mama e próstata. Ex-investigador na Northeastern University em Boston, concentrou-se em biotecnologia farmacêutica e nanomedicina. O Dr. Bilir trabalha numa unidade acreditada pela JCI, onde médicos académicos prestam cuidados 24 horas por dia.

• Membro da Sociedade Americana de Oncologia Clínica (ASCO) e da ESMO.
• Concluiu uma rotação clínica especializada na Cleveland Clinic, nos EUA.
• Trata casos oncológicos complexos, incluindo cancro do pulmão em estádio 4 e sarcomas.
• Atualmente doutorando em química inorgânica na Universidade de Sakarya.

O médico é especializado numa vasta gama de procedimentos estéticos cirúrgicos e não cirúrgicos. A experiência clínica inclui estética nasal, aplicações cirúrgicas faciais, estética mamária e técnicas de contorno corporal, como a lipoaspiração.

Para além das intervenções cirúrgicas, o médico oferece tratamentos estéticos não invasivos avançados, incluindo Botox, preenchimentos dérmicos e procedimentos de mesoterapia, focando-se na melhoria da aparência do paciente através de soluções cosméticas precisas e personalizadas.

A Dra. Meryem Eken é professora e chefe da unidade de FIV no Hospital Medical Park Göztepe. Ela foca na infertilidade, incluindo FIV em ciclo natural e inseminação intrauterina. É vencedora do primeiro prémio da Sociedade Turca de Ginecologia e Obstetrícia. Anteriormente, a Dra. Eken liderou a unidade de FIV no Hospital Hisar Intercontinental.

• Autora de mais de 30 artigos internacionais revistos por pares sobre saúde reprodutiva.
• Realiza miomectomia minimamente invasiva e histerectomia laparoscópica.
• Trata condições complexas como endometriose e perda gestacional recorrente.
• Utiliza terapia PRP para rejuvenescimento ovariano e uterino.

Professora e médica-chefe. Diretora de Oncologia Ginecológica. Doutorado (PhD) em Oncologia Ginecológica pelo Hospital de Câncer da Academia Chinesa de Ciências Médicas. Mestrado em Obstetrícia e Ginecologia pelo Hospital do Peking Union Medical College. Quase 30 anos de experiência clínica. Publicações em revistas SCI e periódicos principais. Coautora de duas monografias sobre oncologia ginecológica.

Especializada em diagnóstico padronizado e tratamento abrangente de cânceres de ovário, colo do útero e endométrio. Oferece cirurgia, quimioterapia, terapia-alvo, imunoterapia e perfusão hipertérmica intraperitoneal. Pioneira em laparoscopia de porta única em seu hospital. Também realiza laparoscopia de múltiplas portas, cirurgia aberta e procedimentos histeroscópicos para doenças ginecológicas benignas.

Afiliações: Diretora de Jovens, Associação Chinesa contra o Câncer. Membro jovem, Comitê de Oncologia Ginecológica, Associação contra o Câncer de Fujian. Membro, Comitê de Tumores Peritoneais, Associação contra o Câncer de Fujian. Membro jovem, Comitê de Obstetrícia e Ginecologia, Associação Médica de Fujian.

O Dr. Irfan Cicin é professor de Oncologia Médica no Hospital İstinye University Liv Topkapı. Especializa-se no tratamento de cancros complexos, incluindo glioblastoma, cancro do pulmão e tumores pancreáticos. É professor na Faculdade de Medicina da Universidade de Trakya. O Dr. Cicin serviu anteriormente como médico na Força Aérea Turca.

• Realiza terapias sistémicas como imunoterapia, quimioterapia e terapia hormonal.
• Trata uma vasta gama de condições, incluindo casos ginecológicos, ortopédicos e neuro-oncológicos.
• Especialista em HIPEC e quimioembolização para neoplasias hepáticas e abdominais.
• Trabalha num hospital universitário de 300 camas com 33 departamentos médicos.

A Dra. Aleksandra Starosciak formou-se na Academia Médica de Varsóvia. É especialista em cirurgia geral desde 2009. Está a tirar uma especialização em cirurgia oncológica. Desde 2010, trabalha no Departamento de Cirurgia Oncológica do Hospital da Sagrada Família em Varsóvia. É membro da Sociedade Polaca de Cirurgia Oncológica. Participa em conferências científicas e de formação em cirurgia geral, oncologia, cirurgia plástica e ecografia mamária.

Realiza cirurgias mamárias, incluindo remoção de tumores, reconstrução e mastectomia. Realiza também procedimentos de tecidos moles e procedimentos menores, como a remoção de lesões cutâneas e nódulos. Realiza cirurgia endócrina para lesões malignas e benignas da tiroide.

Diagnostica doenças mamárias. Realiza biópsias mamárias assistidas por vácuo (mammotome) guiadas por ecografia. Realiza também biópsias por agulha grossa e biópsias por aspiração com agulha fina. Realiza biópsias da tiroide e videodermatoscopia de lesões cutâneas.

A Dra. Kevser Arkan, MD, é subespecialista em cirurgia oncológica ginecológica (OB/GYN) no OPTIMED Health Group em Çorlu e Çerkezköy. Trabalha lá desde 2026. Presta atendimento em inglês e turco.

O seu foco clínico é a gestão cirúrgica de cancros do ovário, endométrio e colo do útero. Realiza procedimentos pélvicos complexos, incluindo histerectomia radical, linfadenectomia com mapeamento de gânglios linfáticos sentinela e citorredução tumoral. Oferece cirurgia minimamente invasiva, incluindo vNOTES (laparoscopia sem cicatrizes), laparoscopia, laparotomia e histeroscopia. Também realiza reconstrução uroginecológica, incluindo sacrocolpopexia. Gere obstetrícia de alto risco.

Credenciais: MD, Universidade de Gaziantep (2016). Residência em OB/GYN, Universidade Kahramanmaraş Sütçü İmam (2016–2021). Fellowship em Cirurgia Oncológica Ginecológica, Hospital de Formação e Investigação Gazi Yaşargil em Diyarbakır (2022–2025). Experiência: Hospital Materno-Infantil de Diyarbakır, Clínica de Oncologia Ginecológica (2022–2025). Hospital Estatal de Adıyaman Kahta (2021–2022). Giresun Alucra TSM (2016).

Trabalho académico: Em 2025, publicou estudos revistos por pares sobre o mapeamento de gânglios sentinela no estadiamento do cancro do endométrio por vNOTES e sobre os resultados de vNOTES versus laparoscopia. Também relatou sobre prolapso de órgãos pélvicos e função sexual, regimes de folato para GTN e sacrocolpopexia assistida por vNOTES. Os seus artigos apareceram em revistas como BMC Surgery, Scientific Reports, Journal of Clinical Medicine e Ginekologia Polska.

O Dr. Josep Tabernero é um oncologista de renome mundial, classificado pela Forbes entre os cinco principais líderes médicos de Espanha. Traz uma vasta experiência em casos oncológicos que requerem biópsia mamária.

• Diretor do Vall d’Hebron Instituto de Oncologia em Barcelona
• Ex-presidente da Sociedade Europeia de Oncologia Médica (ESMO)
• Estágio clínico no MD Anderson Cancer Center da Universidade do Texas
• Membro da Sociedade Americana de Oncologia Clínica (ASCO)
• Premiado pela excelência no tratamento do cancro pela Sociedade Americana de Oncologia Clínica

O Dr. Muhammed Mustafa Atci é professor associado de Oncologia Médica no Liv Hospital Topkapı. Especializa-se no tratamento de cancros do cólon, mama, gástrico e pulmão. Anteriormente, serviu como Coordenador de Educação no Hospital Municipal Prof. Dr. Cemil Taşcıoğlu. O Dr. Atci é membro da Sociedade Americana de Oncologia Clínica (ASCO).

• Autor de 19 artigos revistos por pares sobre cancros gastrointestinais, torácicos e endócrinos.
• Publicou estudos sobre resultados de sobrevivência para cancro do cólon em estádio IIB no Journal of Chemotherapy.
• Investiga biomarcadores prognósticos usando exames PET/CT e volume tumoral metabólico.
• Trata casos oncológicos complexos na clínica universitária İstinye University.

O Dr. Ercan Ozden é oncologista médico e especialista em medicina interna no VM Medical Park Pendik. Ele oferece tratamento para uma ampla gama de cânceres, incluindo câncer de mama, pulmão e cólon. O Dr. Ozden formou-se na Faculdade de Medicina Cerrahpasa da Universidade de Istambul. Posteriormente, completou uma subespecialidade em oncologia médica na Universidade de Kocaeli.

• Especializado em imunoterapia, terapia-alvo e quimioterapia para casos complexos.
• Trata pacientes em um hospital credenciado pela JCI em Istambul.
• Realiza estadiamento e biópsias de tumores de fígado, pulmão e pâncreas.
• Fornece imunoterapia direcionada usando medicamentos como Keytruda.

O Dr. Mustafa Serkan Alemdar é oncologista clínico no complexo hospitalar Medical Park Antalya. Especializa-se no tratamento de tumores sólidos complexos e cancros do sangue. O Dr. Alemdar completou a sua licenciatura em medicina e a sua especialização em oncologia na Universidade de Akdeniz. É membro ativo da Sociedade Turca de Oncologia Médica.

• Trata uma vasta gama de cancros, incluindo o da mama, do pulmão e da próstata.
• Especialista em hematologia-oncologia para doenças como leucemia, mieloma e linfoma.
• Realiza terapias sistémicas como quimioterapia, imunoterapia e terapia biológica direcionada.
• Trabalha numa unidade que dispõe de departamentos especializados em oncologia e medula óssea, bem como tecnologia LINAC.

O Dr. Hasan Mutlu é oncologista médico no complexo hospitalar Medical Park Antalya. Especializa-se em imunoterapia, terapias oncológicas direcionadas e investigação genética no tratamento do cancro. O Dr. Mutlu obteve o seu diploma de medicina na Universidade Hacettepe. Detém o título de Professor de Medicina. O Dr. Mutlu concentra-se no diagnóstico de tumores de órgãos e na quimioterapia.

• Especializado em casos de oncologia médica e pediátrica.
• Trata condições complexas, incluindo neuroblastoma, tumor de Wilms e sarcoma de Ewing.
• Realiza terapias biológicas e mantém-se ativo na investigação genética de nova geração.
• Trabalha no maior hospital privado da região mediterrânica, equipado com tecnologia PET-CT e LINAC.

Dr. Shute Ailia DAE is a medical oncologist at Optimed International Çorlu Hospital. Dr. Ailia graduated from Dokuz Eylül University Faculty of Medicine in 2013 and completed an internal medicine residency at Bezmialem Vakıf University Hospital in 2018. A hematology–oncology fellowship at Başkent University Hospital followed in 2023.

From 2018 to 2020, Dr. Ailia served as an internal medicine specialist at Bezmialem Vakıf University Hospital. From 2023 to 2024, Dr. Ailia was an instructor in medical oncology at Başkent University Adana Dr. Turgut Noyan Practice and Research Center.

Clinical focus includes breast, lung, and prostate cancers. It also covers gastrointestinal cancers (colon, stomach, esophagus, pancreas, liver), lymphomas, melanoma, and gynecologic and genitourinary cancers. Languages: English, Turkish, Swahili.

Assoc. Prof. Priv.-Doz. Dr. Alexander W. Hauswirth is a specialist in internal medicine and haemato‑oncology at JUVENIS. Since 2010, he has served as the lead senior physician for Haematology/Haemostaseology and Oncology at the Clinic for Internal Medicine I, Medical University of Vienna/AKH Vienna, Austria’s largest hospital.

He earned his medical degree from the University of Vienna in 1999. He received the venia docendi in 2010 and was appointed Associate Professor in 2012. He completed an additional haemato‑oncology qualification in 2014. As a Schrödinger Fellow in Salamanca in 2009–2010, he researched CLL stem and precursor cells. He has published regularly since 2000.

Accreditations include Austrian Medical Chamber diplomas in emergency medicine (since 2009) and sports medicine (2018). Awards include the Schrödinger Fellowship (2009), the ÖGHO award (2009), and the European Society of Chemotherapy poster award (2003). Clinical focus: anaemias, leukaemias, lymph node disorders, clotting and anticoagulation, and pre‑operative clearance. Languages: German and English.

O Dr. Erkan Göcen é especialista em Oncologia Radioterápica no Hospital Privado Çerkezköy Optimed (Optimed Health Group). Formou-se na Universidade de Istambul, Faculdade de Medicina (Çapa), em 2003.

Carreira: Treinou e praticou em Oncologia Radioterápica de 2010 a 2012. Trabalhou em instituições de saúde públicas e privadas de 2012 a 2016. Trabalhou no setor médico privado como especialista em Oncologia Radioterápica de 2016 a 2023. Está no Hospital Optimed desde 2024.

Interesses clínicos: cânceres de cérebro, cabeça e pescoço, esôfago, estômago, colorretal, pâncreas, próstata, bexiga, pulmão, tecidos moles (sarcomas), pele, útero e colo do útero, e mama. Afiliações: Sociedade Turca de Oncologia Radioterápica (TROD) e Câmara Médica de Tekirdağ. Idiomas: inglês e turco.

O Dr. Antonio Gosálvez Vega dirige a Unidade de Reprodução Assistida no Quironsalud Madrid. É especializado em FIV e tratamentos de fertilidade complexos. É membro da Sociedade Americana de Medicina Reprodutiva. O Dr. Vega trata condições como endometriose e ovários policísticos num dos hospitais mais conceituados de Espanha.

• Realiza sacrohisteropexia robótica e cirurgia laparoscópica para endometriose.
• Oferece rejuvenescimento ovárico com PRP e terapia de substituição hormonal bioidêntica.
• Ex-professor do Mestrado em Reprodução Humana na Universidade Complutense.
• Membro da Sociedade Europeia de Reprodução Humana.

Zhang Jinshan, male, China’s First M.D. in the Radiation Medicine, CCI (Chinese College of Interventionalists) Master Interventionalist, Director of the Department of Former Radiological Diagnosis at Chinese PLA General Hospital(No.3 in China) Ph.D. of Medicine, Nagasaki University, Japan.

1980–1985: Completed doctoral studies at Nagasaki University, Japan

1968–present: Department of Radiology, Chinese PLA General Hospital

1988: Third Prize of the Military Science and Technology Progress Award

1989–present: Member of Radiological Society of North America(RSNA)

1990–2009: Standing Committee Member of the Radiology and Therapeutic Radiology Committee of the PLA

1991: Second Prize of the Military Science and Technology Progress Award

1992–2008: Group Leader of the Group of Intervention of Chinese Journal of Radiology

1992–2015: Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology

1993: Granted the Lifetime Special Government Allowance of the State Council

1993–2012: Deputy Chief Editor of Chinese Journal of Medical Image Technology

1994: Third Prize of the Military Science and Technology Progress Award

1997: Second Prize of the Military Science and Technology Progress Award

1997–2009: Standing Member of Chinese Society of Radiology

1999: Third Prize of the Military Science and Technology Progress Award

1999–2010: Deputy Director Member of Chinese Society of Interventional Oncology

2002: Second Prize of the Military Science and Technology Progress Award

2005: Third Prize of the Military Science and Technology Progress Award

Member of Radiological Society of North America(RSNA)

Standing Member of Chinese Society of Radiology

Group Leader of the Group of Intervention of Chinese Journal of Radiology

Deputy Director Member of Chinese Society of Interventional Oncology

Director Member of Beijing Medical Association Society of Interventional Radiology

Deputy Chief Editor of Chinese Journal of Medical Image Technology

Standing Member of Professional Committee of Radiological Medicine of the Chinese People’s Liberation Army

Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology

Awarded the Special Government Allowance of the State Council

Awarded three Second Prizes and four Third Prizes for Military Science and Technology Progress.

Awarded the honorary title of “Chinese College of Interventionalists(CCI) Master Interventionalist”

Led multiple national and provincial/ministerial scientific research projects, including two projects funded by the National Natural Science Foundation of China and two projects funded by the Department of Science and Technology of Sichuan Province.

In the pioneering development of interventional medicine in China, Zhang Jinshan has been an indispensable founder and leading figure. As China’s first overseas-trained doctoral graduate in radiological medicine, he returned to China in the 1980s after completing his studies abroad and introduced cutting-edge international interventional technologies to the country. Over more than four decades of dedicated practice and research, he has helped propel Chinese interventional medicine from its infancy to a position at the forefront of the global field through his exceptional clinical expertise and profound academic accomplishments.

Professor Zhang Jinshan has long been dedicated to the field of medical imaging and has developed distinctive expertise in selective and superselective interventional diagnosis and treatment for solid tumors such as liver cancer, demonstrating exceptional technical proficiency and profound academic accomplishment. Beginning in the 1990s, he led his team in pioneering the clinical application and research of TIPSS and B-ORTO in China, filling major gaps in the domestic field and opening new paths for the interventional management of gastrointestinal bleeding caused by portal hypertension secondary to liver cirrhosis. In addition, he has made groundbreaking contributions to the interventional diagnosis and treatment of peripheral vascular diseases, as well as to preoperative embolization for spinal tumors.

In the field of liver cancer treatment, Professor Zhang Jinshan not only led the development of standardized treatment protocols for liver cancer but also pioneered Transcatheter Arterial Chemoembolization with temporary Hepatic Vein Thrombosis (TACE-THVO) for primary liver cancer, bringing the efficacy of interventional therapy to a new level. In recognition of his outstanding clinical and scientific contributions, he was awarded the honorary title of “Chinese Master of Interventional Radiology” at the 2019 annual conference of the Chinese College of Interventionalists.

Professor Zhang Jinshan is not only a master clinician but also a driving force in the development of the discipline and a dedicated mentor in talent cultivation. He led his team in establishing one of China’s premier interventional therapy centers. As a doctoral supervisor, he has trained a large number of outstanding specialists and future leaders in interventional medicine, with many of his students and protégés now serving across the country. Academically, he has led multiple key national and military research projects, published more than 300 academic papers, and served as chief editor of three monographs, making remarkable contributions to the establishment of China’s academic framework for interventional medicine and the nationwide dissemination of its technologies.

From the laboratory to the operating room, and from academic podiums to grassroots hospitals, Professor Zhang Jinshan has consistently upheld the principles of “pioneering, innovation, pragmatism, and compassion". He has devoted his life to fulfilling the mission of a physician—relieving patients’ suffering through minimally invasive techniques and advancing the discipline through academic excellence—thereby establishing himself as a truly towering figure and one of the foremost authorities in the field of interventional medicine in China.

Professor Zhang Jinshan’s Academic Achievements

Professor Zhang Jinshan has achieved prolific academic accomplishments, having published over 300 academic papers covering areas such as interventional therapy for liver cancer, minimally invasive treatment of portal hypertension, interventional treatment of vascular diseases, and tumor ablation.

Selected Publications by Professor Zhang Jinshan

1. Zhang Jinshan, Wang Maoqiang. Experiments and Clinical Studies of transjugular intrahepatic portosystemic stent shunt (TIPSS). Chinese Journal of Radiology, 1993，27（6）：361-365.

Professor Zhang Jinshan is the first author. This is one of the early research papers in China that systematically elaborates on the TIPSS technique. Through animal experiments and clinical case analysis, it confirmed that TIPSS is a safe and effective minimally invasive method for treating portal hypertension and its complications, laying an important foundation for the promotion and application of this technique in China.

2.Zhang Jinshan, Li Huai. Clinical study on transcatheter arterial embolization with temporary hepatic vein occlusion for the treatment of primary liver cancer.Chinese Journal of Radiology, 1996，30（8）：521-524.

Professor Zhang Jinshan is the first author. He innovatively proposed the technique of "transcatheter arterial embolization with temporary hepatic vein occlusion." Clinical results demonstrated that this method can significantly increase the drug concentration within liver cancer lesions, reduce damage to normal liver tissue, and effectively improve the therapeutic outcomes for intermediate and advanced liver cancer, providing a novel strategy for the interventional treatment of liver cancer.

3. Zhang Jinshan, Wang Maoqiang, Li Huai. Interventional treatment of Budd-Chiari syndrome. Chinese Journal of Medical Imaging Technology, 1998，14（3）：189-191.

Professor Zhang Jinshan is the first author. This paper systematically summarizes the early experience in interventional treatment of Budd-Chiari syndrome in China, elaborating in detail on the key operational points and therapeutic efficacy of techniques such as percutaneous transluminal angioplasty and stent placement. It confirms that interventional therapy is the preferred minimally invasive method for Budd-Chiari syndrome, promoting the standardized development of treatment for this disease.

4.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical value of superselective hepatic arterial chemoembolization in the treatment of hypovascular liver cancer. Chinese Journal of Radiology, 2000，34（5）：335-337.

Professor Zhang Jinshan is the first author. Addressing the challenges in interventional treatment of hypovascular liver cancer, this paper explores the clinical efficacy of superselective hepatic arterial chemoembolization. The results indicate that this technique can precisely target the lesions and improve the treatment response rate, providing an important clinical basis for the interventional treatment of hypovascular liver cancer.

5. Zhang Jinshan, Li Huai, Wang Maoqiang. Interventional treatment of peripheral vascular stenosis and occlusion.Chinese Journal of Radiology, 2002，36（7）：612-614.

Professor Zhang Jinshan is the first author. This paper summarizes the interventional treatment experience of over 400 patients with peripheral vascular stenosis and occlusion, analyzing the indications and efficacy of techniques such as balloon angioplasty and stent placement. It confirms that interventional therapy is a safe and effective approach for peripheral vascular diseases, providing practical support for its clinical promotion.

6.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical application of CT-guided percutaneous puncture ablation in the treatment of abdominal tumors. Chinese Journal of Medical Imaging Technology, 2004，20（9）：1395-1397.

Professor Zhang Jinshan is the first author. This paper explores the application value of CT-guided percutaneous puncture techniques such as radiofrequency ablation and chemical ablation in the treatment of abdominal tumors. The clinical results show that this method is minimally invasive with reliable efficacy, offering a minimally invasive treatment option for patients with inoperable abdominal tumors.

7.Zhang Jinshan, Wang Maoqiang, Li Huai. Advances in the application of interventional therapy for benign prostatic hyperplasia. Chinese Journal of Radiology, 2006，40（8）：876-878.

Professor Zhang Jinshan is the corresponding author. This paper systematically reviews the cutting-edge advances in interventional therapy for benign prostatic hyperplasia, including the principles, procedures, and efficacy of techniques such as prostatic artery embolization and stent placement, providing new insights for the minimally invasive treatment of benign prostatic hyperplasia.

8.Zhang Jinshan, Li Huai, Wang Maoqiang. Discussion on the standardization of interventional therapy for liver cancer. Chinese Journal of Practical Surgery, 2008，28（10）：856-858.

Professor Zhang Jinshan is the corresponding author. Drawing on years of clinical experience and research findings, he led the discussion on standardized protocols for interventional therapy of liver cancer, covering key aspects such as preoperative assessment, treatment modality selection, and postoperative management, providing important references for the formulation of clinical guidelines for interventional therapy of liver cancer in China.

Professor Zhang Jinshan co-authored monographs

1. Interventional Radiology (People's Military Medical Press, 1995): The first monograph in China to systematically discuss the theories and techniques of interventional radiology. It comprehensively elaborates on the interventional diagnosis and treatment system for tumors, vascular diseases, and non-vascular diseases, becoming a classic essential textbook for interventional physicians in China.

2.Interventional Therapy for Liver Cancer (People's Health Press, 2001): Focusing on minimally invasive interventions for liver cancer, this book systematically summarizes techniques such as TACE, ablation, and vascular intervention, refines operational standards and the prevention and management of complications, and promotes the standardization of interventional therapy for liver cancer.

3.Interventional Treatment of Portal Hypertension (Science Press, 2005): This book systematically elaborates on minimally invasive techniques for portal hypertension, such as TIPSS and B-ORTO, covering experimental research, clinical procedures, long-term follow-up, and efficacy evaluation, filling the gap in monographs on interventional treatment of portal hypertension in China.

Professor Zhang Jinshan’s Research project

1.The National "Eighth Five-Year Plan" Scientific and Technological Key Project—Clinical and Basic Research on Comprehensive Interventional Therapy for Liver Cancer (Project Leader): This project systematically explored multimodal interventional strategies for liver cancer, established the core regimen of superselective TACE combined with local ablation, and significantly improved the therapeutic outcomes for intermediate and advanced liver cancer.

2.The Military "Ninth Five-Year Plan" Key Medical Scientific Research Project—Standardized Research on TIPSS for the Treatment of Portal Hypertension (Project Leader): This project formulated China's first operational standards and postoperative management guidelines for TIPSS, reduced the incidence of complications, and promoted the popularization of this technique throughout the military and across the country.

3.National Natural Science Foundation of China Project — Research on the Mechanism of Targeted Therapy for Liver Cancer Using Hepatic Vein Occlusion Combined with Chemoembolization (Project Leader): This project revealed the synergistic enhancement mechanisms of the innovative technique at the levels of hemodynamics, drug metabolism, and the tumor microenvironment, providing theoretical support for precision interventional therapy of liver cancer.

4.Military Clinical High-Tech Major Project-Establishment and Clinical Application of the Interventional Treatment Technology System for Complex Vascular Diseases (Project Leader): This project overcame interventional challenges in complex lesions such as Budd-Chiari syndrome, peripheral vascular occlusion, and vascular malformations, forming a complete technical system that has been promoted and applied widely.